According Tracxn report, India’s pharma and healthcare start-up sector recorded a significant downturn in investment activity in June 2025, with total funding reaching $7.2 million across five deals. This represents a 97.07 per cent decline from May 2025, which saw $244.4 million raised, and a 96.16 per cent fall compared to June 2024.
According to market data, the sharp drop in funding comes after a period of recovery in May, when funding levels rebounded by 310 per cent from April 2025’s figure of $59.6 million. However, June reversed that trend, indicating growing investor caution or market recalibration.
Early-stage investments made up the largest share of capital in June 2025, accounting for 65.1 per cent of the total deployed funds. Seed-stage funding followed at 34.9 per cent, suggesting that investors maintained interest in nascent ventures despite overall capital contraction.
Among the top deals, Plush secured the largest round at $4.7 million, making up the majority of capital raised that month. Jantri followed with $1.4 million, Innovodigm raised $0.6 million, and Iom Bioworks closed a $0.5 million round.
Blume Ventures and OTP Ventures were the most active investors during the month, jointly participating in the Plush round. Genesia Ventures backed one funding round for Farmako.
The data shows three key trends for June 2025: a significant drop in total funding, a concentration of capital in early-stage rounds, and the absence of any major outlier deals. In comparison to the previous month’s highest deal of $156 million, the top deal in June was significantly smaller, underlining the scale of the overall contraction.
The post Pharma and healthcare start-up funding falls in June 2025 appeared first on Express Healthcare.
